The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)
NCT ID: NCT00421278
Last Updated: 2016-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
180 participants
INTERVENTIONAL
2006-11-30
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
NCT00804843
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
NCT00853827
Monocyte Activation in Preclinical Atherosclerosis
NCT02126280
High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients
NCT05912686
Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis
NCT00723320
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Arm 1: Drug
MK0633
Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK0633
Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inflammatory marker found in your blood, known as hsCRP \> 0.5 mg/L
Exclusion Criteria
* Female
* Heart attack, coronary artery bypass, stroke or unstable angina in last 3 months
* Liver diseased or abnormalities
* HIV infection
* Lupus, rheumatoid arthritis, cancer \<5 years
40 Years
85 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK0633-008
Identifier Type: -
Identifier Source: secondary_id
2006_563
Identifier Type: -
Identifier Source: secondary_id
0633-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.